The Virus Project
    Facebook Twitter Instagram
    The Virus Project
    • Home
    • Invest in Schools Summit
      • Summary
      • Strategy
      • Agenda
      • Speakers
      • White Papers
      • Register
      • Purchase Tickets
      • COVID Safety
      • Venues  
      • Live Streaming
    • Events
      • Back to School Conference
        • Videos
        • Summary
        • Sponsors
        • Agenda
        • Speakers
      • The Contagion Conference
    • Initiatives
      • Overview
      • University Research Network
      • Impact Investment Network
    • Approaches
      • Testing
      • Containment
      • Therapies
      • Vaccines
    • Resources
      • Research Library
      • COVID Tests Research Report
      • Marketplace
      • Organizations
      • Media Resources
    • About
      • THE VIRUS PROJECT
      • About the Site
      • Virus Project Team
      • Altru Institute
      • Newsletters
      • Open Source Journalism
      • Join
        • Back to School Conference Registration
        • Join to BEAT COVID
        • Invest
    • Log In
    The Virus Project
    You are at:Home»Vaccines»Category: "Vaccine Tech"

    Browsing: Vaccine Tech

    Moderna in partnership with the NIH begin phase three trials for COVID vaccine

    0
    By VP Staff on July 27, 2020 Vaccine Tech, Vaccines

    SUMMARY: The first injection for Moderna’s vaccine trail in partnership with the National Institutes of Health aims to enroll about 30,000 people from 89 widely dispersed sites across the U.S. It is the first possible coronavirus vaccine to enter a phase three trial in the U.S.  If the vaccine remains on track, Moderna previously said it will be able to deliver “approximately 500 million doses per year, and possibly up to 1 billion doses per year” starting in 2021.The company announced earlier this month that healthy adults whowere given the vaccine in the phase one trial tolerated it generally well and all…

    Read More

    US orders $1.95 Billion Covid-19 Vaccine from Pfizer and BioNTech

    0
    By VP Staff on July 18, 2020 NEWS, Vaccine Tech, Vaccines

    The U.S. has agreed to pay Pfizer Inc. and BioNTech SE nearly $2 billion to secure 100 million doses of their experimental Covid-19 vaccine to provide to all Americans free of charge. Under the $1.95 billion agreement, the U.S. Department of Health and Human Services and the Defense Department will receive 100 million doses of the vaccine should it be cleared by regulators, and can also acquire an additional 500 million doses. The U.S. has already made other agreements including a $1.2 billion deal with AstraZeneca PLC for at least 300 million doses of a vaccine developed by University of Oxford.…

    Read More

    BioNTech confident that COVID vaccine will be ready December 2020.

    0
    By VP Staff on July 10, 2020 Vaccine Tech, Vaccines

    SUMMARY: BioNTech expects to begin phase three trials, at the end of July. Gilead Sciences also announced that test results on remdesivir, the only approved treatment for COVID-19, shows a reduction in mortality in 62 percent of extremely sick patients. Optimism from a potential vaccine and the success of remdesivir also resulted in spike in the US stock market.   Abridged. The CEO of the German company BioNTech told The Hill that he expects the coronavirus vaccine the company is developing in partnership with Pfizer to be ready for approval by December. BioNTech CEO Ugur Sahin said several hundred million doses could be produced even before approval and up to 1.2…

    Read More
    VIRUS PROJECT UPDATES
    September 13, 2021

    New Approach to K-12 Education. Self-Directed Model to Present at Altru Salon

    June 9, 2021

    Altru Virus Project Summit in DC to Focus on Stronger Schools

    June 8, 2021

    Core Curriculum for Invest in Schools Summit

    January 26, 2021

    How to Reopen Schools and Keep Them Open. A Virus Project White Paper

    September 1, 2020

    University Fellowships. A Global Network of Scientists to Address Big Challenges like COVID

    About

    The global communications platform for those collaborating to beat the Coronavirus.
    INITIATIVES
    • Invest in Schools Summit
    • University Research Consortium
    • Impact Investment Network
    Links

    Editorial Approach

    Submit Stories/Projects

    Contact Us

    Account Login

    Copyright © 2020

    Type above and press Enter to search. Press Esc to cancel.